April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Protective effect Of Intravitreal Administration Of Tresperimus, An Immunosuppressive Drug, On Experimental Autoimmune Uveoretinitis
Author Affiliations & Notes
  • Elodie Bousquet
    Ophthalmology,
    Centre de Recherche des Cordeliers UMRS 872, Paris, France
  • Serge Camelo
    Centre de Recherche des Cordeliers, UMRS 872, Equipe 21 P5, P6, INSERM, Paris, France
  • Jocelyne Annat
    50 rue de Dijon, Laboratoire Fournier, Daix, France
  • Francine Behar-Cohen
    ophthalmology,
    Centre de Recherche des Cordeliers UMRS 872, Paris, France
  • Yvonne de Kozak
    ophthalmology,
    Centre de Recherche des Cordeliers UMRS 872, Paris, France
  • Footnotes
    Commercial Relationships  Elodie Bousquet, None; Serge Camelo, None; Jocelyne Annat, pharmaceutical company (F); Francine Behar-Cohen, None; Yvonne de Kozak, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 6582. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elodie Bousquet, Serge Camelo, Jocelyne Annat, Francine Behar-Cohen, Yvonne de Kozak; Protective effect Of Intravitreal Administration Of Tresperimus, An Immunosuppressive Drug, On Experimental Autoimmune Uveoretinitis. Invest. Ophthalmol. Vis. Sci. 2011;52(14):6582.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To test the efficiency of Tresperimus, animmunosuppressive drug, in experimental autoimmune uveoretinitis (EAU).

 
Methods:
 

EAU was induced in Lewis rats by S-Ag immunization. Three intravitreal injections of Tresperimus were performed during the afferent phase of EAU. Pharmacokinetics of Tresperimus was performed in ocular tissues and plasma. Ocular disease severity was graded by clinical, histological and immunohistochemistry analysis. Blood ocular barrier permeability was evaluated by protein concentration in ocular fluids. The activation of macrophages was checked by in vitro treatment. Immune response to S-Ag was examined by delayed type hypersensitivity (DTH), titration of inflammatory cytokines in lymph nodes and in infiltrated cells in ocular fluids by RT-PCR and in ocular fluids by multiplex ELISA.

 
Results:
 

Tresperimus could be detected in the ocular milieu up to 8 days following last injection but was not detectable in plasma of treated rats. Tresperimus treatment protected against retinal damages with reduction of blood ocular barrier permeability breakdown. Tresperimus suppressed the expression of NOS-2 and reduced NF-ΚBp65 nuclear expression in ocular macrophages suggesting a change of their phenotype. Further, in vitro it significantly reduced production of CCL-3 by macrophages, and in vivo the intraocular concentration of the T cell cytokines IL-2, IL-17, but increased that of IL-18. By contrast, in inguinal lymph nodes draining the immunization site, Tresperimus treatment did not modify the level of IL-2, IL-17. Moreover, DTH to S-Ag was not different in control and treated rats. Altogether, the treatment did not modify the systemic T cell reactivity to S-Ag.

 
Conclusions:
 

Intraocular Tresperimus treatment regulated macrophage activation and reduced Th-17 T cell mediated response in the eye with no modification of the systemic immune response.  

 
Keywords: uveitis-clinical/animal model • pathology: experimental • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×